Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Johnson & Johnson (JNJ) PT Raised to $185 at Goldman Sachs
July 17, 2025 6:07 AM EDTGoldman Sachs analyst Asad Haider raised the price target on Johnson & Johnson (NYSE: JNJ) to $185.00 (from $177.00) while maintaining a Buy rating.
The analyst comments "In a backdrop where we had that noted our investor conversations suggest sentiment shifting slightly more positive on the tactical setup for US pharma into 2Q earnings season (see: link), JNJ shares... More
Johnson & Johnson (JNJ) Tops Q2 EPS by 9c, Beats on Revenue; Offers Strong FY25 Guidance
July 16, 2025 6:21 AM EDTJohnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.77, $0.09 better than the analyst estimate of $2.68. Revenue for the quarter came in at $23.74 billion versus the consensus estimate of $22.86 billion.
GUIDANCE:
Johnson & Johnson sees FY2025 EPS of $10.63-$10.73, versus the consensus of $10.61.... More
